MARK JONES: Open Payments
NPI 1982949657 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$637 in 20 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $637
Food & beverage: $526Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 10 | $347 |
| Janssen Pharmaceuticals, Inc | 2 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| ABBVIE INC. | 2 | $42 |
| Alkermes, Inc. | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
Products named: UZEDY, INVEGA SUSTENNA, CAPLYTA, VRAYLAR, ARISTADA, COBENFY, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
